share_log

Nava Health MD, Inc. and 99 Acquisition Group, Inc. Announce Merger Agreement for Nava Health To Become a Publicly Traded Entity

Nava Health MD, Inc. and 99 Acquisition Group, Inc. Announce Merger Agreement for Nava Health To Become a Publicly Traded Entity

Nava Health MD, Inc. 和 99 Acquisition Group, Inc. 宣布 Nava Health 成为上市实体的合并协议
Accesswire ·  02/13 05:00
  • Nava Health MD, Inc. ("Nava Health") has entered into a definitive merger agreement with 99 Acquisition Group, Inc. (NASDAQ:NNAG)
  • Nava Health is an emerging innovator providing integrative, functional, preventative, and regenerative healthcare
  • Nava Health 2023 Revenues grew approximately 81% driven by significantly increased customer visits and improved location economics
  • Strong shareholder alignment with team led by Nava Health founder Bernie Dancel
  • Transaction represents potential equity value of $320 million for Nava Health
  • Transaction expected to be complete in second quarter 2024, subject to regulatory approvals and other closing conditions
  • Nava Health MD, Inc.(“Nava Health”)已与99收购集团公司(纳斯达克股票代码:NNAG)签订了最终合并协议
  • Nava Health 是一家新兴的创新者,提供综合性、功能性、预防性和再生性医疗保健
  • Nava Health 2023 年收入增长了约 81%,这得益于客户访问量显著增加和位置经济的改善
  • 股东与由 Nava Health 创始人伯尼·丹塞尔领导的团队保持着密切的合作关系
  • 这笔交易意味着Nava Health的潜在股权价值为3.2亿美元
  • 交易预计将于2024年第二季度完成,但尚待监管部门批准和其他成交条件

COLUMBIA, MD / ACCESSWIRE / February 13, 2024 / Nava Health MD, Inc. ("Nava Health"), a vertically integrated, tech-enabled chain of healthcare centers that combines integrative, functional, preventive, and regenerative medicine, and 99 Acquisition Group, Inc. (NASDAQ:NNAG), a publicly traded special purpose acquisition company ("99 Acquisition"), today announced they have entered into a definitive merger agreement (the "Merger Agreement"). Upon closing the proposed transaction, 99 Acquisition will be renamed Nava Health MD, Inc. and expects to remain listed on the Nasdaq Stock Market.

马里兰州哥伦比亚/ACCESSWIRE/2024年2月13日/Nava Health MD, Inc.(“Nava Health”)是一家垂直整合、以技术为导向的医疗保健中心连锁机构,集整合、功能、预防和再生医学于一体,与上市的特殊目的收购公司99收购集团有限公司(纳斯达克股票代码:NNAG)(“99收购”)今天宣布,他们已签订最终合并协议(“合并协议”)。拟议交易完成后,99收购将更名为Nava Health MD, Inc.,预计将继续在纳斯达克股票市场上市。

Hiren Patel, Chairman and Chief Executive Officer of 99 Acquisition, commented, "Nava Health provides a compelling investment opportunity for our stockholders. Management has demonstrated impressive growth to date and is creating a premier brand in a quickly growing market sector. We are confident that the Nava Health team is positioned to continue to scale the business to drive profitability, growth and long term returns for stockholders."

99 Acquisition董事长兼首席执行官希伦·帕特尔评论说:“Nava Health为我们的股东提供了一个引人注目的投资机会。迄今为止,管理层已表现出令人印象深刻的增长,并且正在快速增长的市场领域中打造一流品牌。我们相信,Nava Health团队有能力继续扩大业务规模,以推动股东的盈利能力、增长和长期回报。”

Bernie Dancel, CEO of Nava Health, welcomed the signing of the agreement, saying, "We are at an exciting point in our growth, coming off of a strong 2023 with significant increases to our customer base which drove considerable improvements in the unit economics at our locations. Not every person responds to traditional healthcare options, and I founded this company with the mission to help our clients 'feel their 100%' through comprehensive, personalized, wellness treatment plans, services and products. Our goal is to significantly broaden the reach of our data driven approach to the development of customized treatments. We have seen tremendous growth in the past year from our four existing locations averaging over $6 million per location, which we believe is a testament to the increasing demand for personalized healthcare solutions. In fact, with the demand we are seeing for our offerings, we have started our national expansion with eight new locations currently under lease and expected to open this year. Furthermore, following the closing of this transaction, we anticipate opening additional locations in 2024 and 2025. We believe listing on Nasdaq through a partnership with 99 Acquisition is an ideal pathway for us to raise additional capital and fund our strategic initiatives going forward."

Nava Health首席执行官伯尼·丹塞尔对协议的签署表示欢迎,他说:“我们正处于令人兴奋的增长时刻,2023年强劲地结束了,客户群显著增加,这推动了我们所在地单位经济的显著改善。并非每个人都会对传统的医疗保健选择做出反应,我创立这家公司的使命是通过全面、个性化的健康治疗计划、服务和产品帮助我们的客户 “感受百分之百的感受”。我们的目标是显著扩大我们开发定制疗法的数据驱动方法的覆盖范围。在过去的一年中,我们看到了四个现有地点的巨大增长,每个地点的平均收入超过600万美元,我们认为这证明了对个性化医疗解决方案的需求不断增长。实际上,鉴于我们对产品的需求,我们已经开始了全国扩张,目前有八个新地点正在租赁中,预计将于今年开业。此外,在本次交易完成后,我们预计将在2024年和2025年开设更多地点。我们认为,通过与99 Acquisition的合作在纳斯达克上市是我们筹集额外资金并为未来战略计划提供资金的理想途径。”

Nava Health uses AI-powered technology, proprietary data and automation to drive the continuous optimization of Nava Health's backend systems, front end client support and medical outcomes. Nava Health's Customized Vitality Plans (CVP) factor in medical history, proprietary Q&A data and advanced diagnostics to generate personalized treatment plans, reducing manual workload and empowering patients. Nava Health's revenue has grown from $6.7 million in 2021 to approximately $24.8 million in 2023. The revenue for 2023 grew approximately 81% when compared to 2022 revenue, with Adjusted EBITDA growth of approximately 173% in 2023. Additionally, Nava Health saw an approximate 62% increase in total appointments in 2023, with an approximate 12% increase in revenue per appointment.

Nava Health使用人工智能技术、专有数据和自动化来推动Nava Health的后端系统、前端客户支持和医疗结果的持续优化。Nava Health的定制活力计划(CVP)考虑了病史、专有的问答数据和高级诊断,以制定个性化治疗计划,减少手动工作量并增强患者能力。Nava Health 的收入已从 2021 年的 670 万美元增长到 2023 年的约 2480 万美元。与2022年的收入相比,2023年的收入增长了约81%,调整后的息税折旧摊销前利润在2023年增长了约173%。此外,Nava Health在2023年的总预约人数增长了约62%,每次预约的收入增长了约12%。

The aforementioned financial data for the year ended December 31, 2023 is unaudited. This information is preliminary and subject to change. As such, Nava Health's actual results may differ from the estimated preliminary results provided herein.

截至2023年12月31日止年度的上述财务数据未经审计。此信息为初步信息,可能会发生变化。因此,Nava Health的实际结果可能与此处提供的初步估计结果有所不同。

Key Transaction Terms

关键交易条款

99 Acquisition has entered into a Merger Agreement with Nava Health, dated February 12, 2024, pursuant to which 99 Acquisition will acquire 100% of the equity securities of Nava Health, with Nava Health becoming a wholly-owned subsidiary of 99 Acquisition. In exchange for their equity securities, the shareholders of Nava Health will receive an aggregate number of shares of common stock of 99 Acquisition having a total value equal to $320 million at the closing of the proposed transaction.

99 Acquisition已与Nava Health签订了日期为2024年2月12日的合并协议,根据该协议,99收购将收购Nava Health100%的股权证券,Nava Health成为99收购的全资子公司。作为股权证券的交换,Nava Health的股东将在拟议交易结束时获得99次收购的总价值等于3.2亿美元的普通股。

The proposed transaction has been approved by the boards of directors of Nava Health and 99 Acquisition. The proposed transaction is subject to approval by the stockholders of 99 Acquisition and the shareholders of Nava Health, as well as the satisfaction or waiver of other customary closing conditions, including a registration statement on Form S-4 containing a proxy statement/prospectus being filed with and declared effective by the U.S. Securities and Exchange Commission (the "SEC").

拟议的交易已获得Nava Health和99收购董事会的批准。拟议的交易须经99收购股东和Nava Health股东的批准,以及满足或放弃其他惯例成交条件,包括S-4表格上的注册声明,其中包含向美国证券交易委员会(“SEC”)提交并宣布生效的委托书/招股说明书。

Any cash remaining on the combined company's balance sheet at the closing of the proposed transaction, after any potential shareholder redemptions and the settlement of transaction-related expenses, is expected to be utilized by the combined company for working capital, growth, and other general corporate purposes. The proposed transaction is expected to be completed in the second quarter of 2024.

在拟议交易结束时,在任何潜在的股东赎回和交易相关费用结算后,合并后的公司资产负债表上剩余的任何现金预计将由合并后的公司用于营运资金、增长和其他一般公司用途。拟议的交易预计将于2024年第二季度完成。

Additional information about the proposed transaction, including a copy of the Merger Agreement and an investor presentation, will be provided in a Current Report on Form 8-K to be filed by 99 Acquisition with the SEC and available at www.sec.gov.

有关拟议交易的更多信息,包括合并协议的副本和投资者陈述,将在99 Acquisition向美国证券交易委员会提交的8-K表最新报告中提供,该报告可在www.sec.gov上查阅。

Investor Conference Call Information

投资者电话会议信息

Nava Health and 99 Acquisition Group will host a conference call to discuss the proposed transaction, today, February 13, 2024 at 10am ET. A slide deck will accompany the prepared remarks.

Nava Health和99收购集团将于今天,即美国东部时间2024年2月13日上午10点举行电话会议,讨论拟议的交易。准备好的讲话将附上幻灯片。

To join the call via telephone, please dial (888) 506-0062 (US) or (973) 528-0011 (International) and use code 781124. The call may also be accessed using the following link:

要通过电话加入通话,请拨打 (888) 506-0062(美国)或(973)528-0011(国际)并使用代码 781124。也可以使用以下链接访问该电话:

A replay of the teleconference will be available by dialing (877) 481-4010 (US) or (919) 882-2331 (International), using code 49878. The replay will be available through February 21, 2024.

使用代码49878拨打(877)481-4010(美国)或(919)882-2331(国际)即可重播电话会议。重播将持续到2024年2月21日。

Advisors

顾问

Gordon Feinblatt LLC is serving as legal counsel for Nava Health and Loeb & Loeb LLP is serving as legal counsel for 99 Acquisition.

Gordon Feinblatt LLC担任Nava Health的法律顾问,Loeb & Loeb LLP担任99收购的法律顾问。

About Nava Health:

关于 Nava Health:

Nava Health is a leading integrative medical center committed to providing client-centered, functional, and integrative healthcare. With a team of highly skilled medical professionals and a dedication to cutting-edge technology, Nava Health aims to redefine the healthcare experience. By combining traditional medicine with complementary therapies, Nava Health delivers personalized care that addresses the root causes of health issues. Nava Health is at the forefront of the integrative healthcare movement with multiple centers nationwide.

Nava Health是一家领先的综合医疗中心,致力于提供以客户为中心、功能性和综合性的医疗保健。Nava Health拥有一支由高技能医疗专业人员组成的团队,致力于尖端技术,旨在重新定义医疗体验。通过将传统医学与补充疗法相结合,Nava Health提供个性化护理,解决健康问题的根本原因。Nava Health处于综合医疗保健运动的最前沿,在全国设有多个中心。

About 99 Acquisition

关于 99 收购

99 Acquisition Group, Inc. is a blank check company that was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.

99 Acquisition Group, Inc. 是一家空白支票公司,成立的目的是与一个或多个企业或实体进行合并、股票交换、资产收购、股票购买、资本重组、重组或其他类似的业务合并。

Important Information about the Proposed Business Combination and Where to Find It

有关拟议业务合并的重要信息以及在哪里可以找到它

This press release relates to a proposed transaction between 99 Acquisition and Nava Health. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed business combination, 99 Acquisition, Nava Health and/or a successor entity of the transaction intends to relevant materials with the SEC, including a registration statement on Form S-4 containing a proxy statement/prospectus (the "Registration Statement") with the SEC. The Registration Statement will include a proxy statement/prospectus to be distributed to holders of 99 Acquisition's common stock in connection with 99 Acquisition's solicitation of proxies for the vote by 99 Acquisition's stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to Nava Health's shareholders in connection with the proposed business combination. After the Registration Statement has been filed and declared effective, 99 Acquisition will mail a definitive proxy statement, when available, to its stockholders.

本新闻稿涉及99收购与Nava Health之间的拟议交易。本新闻稿不构成出售或交换任何证券的要约,也不构成购买或交换任何证券的要约,在根据任何此类司法管辖区的证券法进行注册或获得资格认证之前,任何司法管辖区均不得进行任何证券的出售。关于拟议的业务合并,99收购、Nava Health和/或该交易的继任实体打算向美国证券交易委员会提供相关材料,包括一份载有美国证券交易委员会委托书/招股说明书(“注册声明”)的S-4表格注册声明。注册声明将包括一份委托书/招股说明书,该委托书/招股说明书将分发给99 Acquisition普通股的持有人,该委托书涉及99 Acquisition的股东就拟议交易和注册声明中描述的其他事项征集代理人进行投票,以及与向Nava Health股东发行的证券发行有关的招股说明书。注册声明提交并宣布生效后,99 Acquisition将向其股东邮寄一份最终的委托书(如果有)。

Before making any voting or investment decision, investors and security holders and other interested parties are urged to read the Registration Statement, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about 99 Acquisition, Nava Health and the proposed business combination. Copies of these documents may be obtained free of charge at the SEC's website at www.sec.gov. The documents filed by 99 Acquisition with the SEC also may be obtained free of charge upon written request to 99 Acquisition at c/o 99 Acquisition Corp., 14 Noblewood Ct, Gaithersburg, MD 20878.

在做出任何投票或投资决定之前,我们敦促投资者和证券持有人和其他利益相关方仔细阅读注册声明、其任何修正案以及向美国证券交易委员会提交的任何其他文件,因为它们将包含有关99收购、Nava Health和拟议业务合并的重要信息。这些文件的副本可以在美国证券交易委员会的网站www.sec.gov上免费获得。99 Acquisition向美国证券交易委员会提交的文件也可以在马里兰州盖瑟斯堡的诺布尔伍德康涅狄格州14号的99收购公司书面申请后免费获得。

Participants in the Solicitation

招标参与者

99 Acquisition and its directors and executive officers may be deemed participants in the solicitation of proxies from 99 Acquisition's securityholders with respect to the proposed transaction under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain executive officers and directors of 99 Acquisition in the solicitation by reading 99 Acquisition's Registration Statement and other relevant materials filed with the SEC in connection with the proposed transaction when they become available. Information about 99 Acquisition's directors and executive officers and their ownership of 99 Acquisition's common stock is set forth in its prospectus related to its initial public offering dated August 21, 2023. Other information regarding the interests of participants in the proxy solicitation, which, in some cases, may be different from those of 99 Acquisition's securityholders generally, will be set forth in the Registration Statement relating to the transaction when it becomes available. These documents can be obtained free of charge at the SEC's web site at www.sec.gov.

根据美国证券交易委员会的规定,99 Acquisition及其董事和执行官可被视为参与向99 Acquisition的证券持有人就拟议交易征集代理人。证券持有人可以在招标中阅读99 Acquisition的注册声明和向美国证券交易委员会提交的与拟议交易相关的其他相关材料,以获得有关99 Acquisition的某些执行官和董事的姓名、隶属关系和利益的更多详细信息。有关99 Acquisition董事和执行官及其对99 Acquisition普通股所有权的信息,见其2023年8月21日与首次公开募股相关的招股说明书。有关代理招标参与者利益的其他信息,在某些情况下,这些信息可能与99 Acquisition证券持有人的总体利益不同,这些信息将在与该交易相关的注册声明发布后列出。这些文件可以在美国证券交易委员会的网站www.sec.gov上免费获得。

Nava Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from 99 Acquisition's securityholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction will be included in the Registration Statement for the proposed transaction.

Nava Health及其董事和执行官也可能被视为参与向99 Acquisition的证券持有人征集与拟议交易有关的代理人。此类董事和执行官的姓名清单以及有关他们在拟议交易中的权益的信息将包含在拟议交易的注册声明中。

Non-Solicitation

非招揽行为

This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

本新闻稿不是关于任何证券或拟议交易的委托书或委托书、同意书或授权书。本新闻稿也不构成出售要约或征求购买任何证券的要约,在根据任何此类司法管辖区的证券法进行注册或获得资格认证之前,任何州或司法管辖区均不得出售任何证券。除非通过符合经修订的1933年《证券法》第10条要求的招股说明书或该条款的豁免,否则不得发行证券。

Forward-Looking Statements

前瞻性陈述

Certain statements made in this press release are "forward-looking statements" within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the parties' ability to close the proposed transaction, the anticipated benefits of the proposed transaction, and the financial condition, results of operations, earnings outlook and prospects of 99 Acquisition and/or the proposed transaction and may include statements for the period following the consummation of the proposed transaction. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

本新闻稿中的某些陈述是1995年《美国私人证券诉讼改革法》安全港条款所指的 “前瞻性陈述”,包括有关双方完成拟议交易的能力、拟议交易的预期收益以及99收购和/或拟议交易的财务状况、经营业绩、收益前景和前景的陈述,可能包括拟议交易完成后的声明。此外,任何涉及未来事件或情况的预测、预测或其他描述的陈述,包括任何基本假设,均为前瞻性陈述。前瞻性陈述通常用 “计划”、“相信”、“预期”、“打算”、“展望”、“估计”、“预测”、“项目”、“继续”、“可能”、“可能”、“可能”、“可能”、“可能”、“潜在”、“预测”、“应该”、“将” 等词语以及其他类似的词语和表述来识别,但缺少这些词语不是意味着陈述不是前瞻性的。

The forward-looking statements are based on the current expectations of the management of 99 Acquisition and Nava Health, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including: risks related to Nava Health's businesses and strategies; the ability to complete the proposed transaction due to the failure to obtain approval from the shareholders of 99 Acquisition and/or Nava Health or satisfy other closing conditions set forth in the Merger Agreement; the amount of any redemptions by existing holders of 99 Acquisition's common stock; the ability to recognize the anticipated benefits of the proposed transaction; other risks and uncertainties included under the header "Risk Factors" in the Registration Statement to be filed by 99 Acquisition, Nava Health and/or a successor entity of the proposed transaction, in the final prospectus of 99 Acquisition for its initial public offering dated August 21, 2023; and in 99 Acquisition's other filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Nava Health and 99 Acquisition assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Nava Health nor 99 Acquisition gives any assurance that Nava Health, 99 Acquisition or the combined company will achieve its expectations.

前瞻性陈述基于99 Acquisition和Nava Health管理层当前的预期(如适用),本质上受不确定性和情况变化及其潜在影响的影响,仅代表截至该声明发布之日。无法保证未来的发展会是预期的。这些前瞻性陈述涉及许多风险、不确定性或其他假设,可能导致实际结果或业绩与这些前瞻性陈述所表达或暗示的结果或业绩存在重大差异,包括:与Nava Health的业务和战略相关的风险;由于未能获得99收购和/或Nava Health股东批准或满足合并协议中规定的其他成交条件而完成拟议交易的能力;现有赎回的金额99 Acquisition普通股的持有人;确认拟议交易预期收益的能力;99 Acquisition、Nava Health和/或拟议交易的继任实体提交的注册声明、2023年8月21日99收购首次公开募股的最终招股说明书以及99 Acquisition向美国证券交易委员会提交的其他文件中 “风险因素” 标题下包含的其他风险和不确定性。这些文件确定并解决了其他重要的风险和不确定性,这些风险和不确定性可能导致实际事件和结果与前瞻性陈述中包含的事件和结果存在重大差异。前瞻性陈述仅代表其发表之日。提醒读者不要过分依赖前瞻性陈述,Nava Health和99 Acquisition不承担任何义务,也不打算更新或修改这些前瞻性陈述,无论是由于新信息、未来事件还是其他原因。Nava Health和99收购均未保证Nava Health、99收购或合并后的公司将实现其预期。

For more information contact:

欲了解更多信息,请联系:

Nava Health MD, Inc.
John Nesbett/Jennifer Belodeau
IMS Investor Relations
Phone: (203) 972-9200
Email: nava@imsinvestorrelations.com

Nava Health MD, Inc.
约翰·内斯贝特/詹妮弗·贝洛多
IMS 投资者关系
电话:(203) 972-9200
电子邮件:nava@imsinvestorrelations.com

99 Acquisition Group, Inc.
Hiren Patel, CEO
Phone: 703-371-4260
Email: hpatel@intelvative.com

99 收购集团有限公司
首席执行官希伦·帕特尔
电话:703-371-4260
电子邮件:hpatel@intelvative.com

SOURCE: Nava Health

来源:Nava Health


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发